Biotech

Latest Articles

Cassava pays $40M over purportedly confusing Alzheimer's update

.Cassava Sciences has accepted pay out $40 million to address an inspection into insurance claims it...

Merck bags possibilities on Evaxion's AI-designed injection candidates

.Merck &amp Co. has picked up choices on 2 Evaxion Biotech vaccine applicants, paying $3.2 thousand ...

Enanta's RSV antiviral crushes viral tons in challenge research study

.Enanta Pharmaceuticals has actually linked its own respiratory syncytial virus (RSV) antiviral to s...

Biogen cans SAGE-324 collaboration after vital trembling fall short

.Biogen has actually conducted the final ceremonies to its partnership along with Sage Rehabs on SAG...

AbbVie Parkinson's drug from $8.7 B Cerevel acquistion ratings

.On the exact same time that some Parkinson's disease medicines are actually being actually called i...

Arch closes $3B-plus fund to foster biopharma upstarts

.On the heels of a $3 billion fund from Bain Funds Lifestyle Sciences, Arch Venture Partners is actu...

Orion to make use of Aitia's 'electronic doubles' to discover brand-new cancer drugs

.Finnish biotech Orion has snooped prospective in Aitia's "electronic twin" specialist to develop ne...

Windtree's shock med brings up blood pressure in most up-to-date phase 2 gain

.While Windtree Rehabs has actually strained to increase the financial roots needed to have to make ...

2 cancer biotechs combine, making worldwide impact

.OncoC4 is taking AcroImmune-- and also its own in-house professional production capabilities-- unde...

Amgen reports first period 3 gain for $400M chronic eczema drug

.Amgen has discussed (PDF) the first phase 3 records on its own $400 million dermatitis drug, linkin...

Biogen, UCB record phase 3 lupus win after falling short earlier test

.Biogen and also UCB's bank on developing right into phase 3 astride a failed research seeks to have...

Aptadir really hopes new RNA inhibitors can easily turn around tricky cancers

.Italian biotech Aptadir Therapeutics has actually launched along with the guarantee that its own pi...

Wave surfs DMD effectiveness to regulators' doors, sending stockpile

.Surge Life Sciences has satisfied its objective in a Duchenne muscle dystrophy (DMD) research, posi...

Sanofi tweezes brand new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma crease, taking up th...

Achilles splashes cell treatment plan, bandages for cutbacks after missing out on 'business viability' goals

.Achilles Therapeutics has actually shreded its own technique. The English biotech is actually quiti...

Aligos trumpets phase 2 MASH win, lowering liver body fat approximately 46%

.Aligos Rehabs is declaring a midstage succeed in metabolic-dysfunction associated steatohepatitis (...

Basilea ratings $268M BARDA funding for antifungals, antibiotics

.Basilea Pharmaceutica's work building new antifungals has gotten a notable improvement from the U.S...

Capricor markets Europe liberties to late-stage DMD therapy for $35M

.Possessing presently scooped up the united state legal rights to Capricor Therapeutics' late-stage ...

FDA junks adcomm for Applied's unusual condition medication

.After pushing the selection date for Applied Rehabs' metabolic problem medication govorestat, the F...

Novo inks $600M NanoVation deal to examine hereditary drugs ex-liver

.Novo Nordisk is continuing its press in to genetic medicines, accepting pay NanoVation Therapeutics...